| Sex |
| Male |
25 (80.6%) |
| Female |
6 (19.4%) |
| ECOG Status |
| 0–1 |
29 (93.5%) |
| 2 |
2 (6.5%) |
| Median age (range), years |
59 (44–78) |
| Primary tumor site |
| Oral cavity |
11 (35.5%) |
| Larynx |
3 (9.7%) |
| Hypopharynx |
8 (25.8%) |
| Oropharynx |
9 (29.0%) |
| p16 status (oropharyngeal carcinoma) |
| Positive |
3 (33.3%) |
| Negative |
5 (55.6%) |
| Not evaluable |
1 (11.1%) |
| Alcohol abuse |
| No |
10 (37.0% |
| Yes |
17 (63.0%) |
| Not evaluable |
4 |
| Nicotine abuse |
| No |
2 (7.1%) |
| Yes |
26 (92.9%) |
| Not evaluable |
3 |
| Cycles (range) |
3 (1–9) |
| Median duration of treatment |
2.1 months |
| Previous treatment |
| Surgery alone |
1 (3.2%) |
| Surgery plus radiotherapy |
2 (6.5%) |
| Surgery plus concomitant chemoradiotherapy |
5 (16.1%) |
| Primary radiotherapy |
2 (6.5%) |
| Primary concomitant chemoradiotherapy |
14 (45.2%) |
| Primary radioimmunotherapy |
3 (9.6%) |
| Radioimmunotherapy |
4 (12.9%) |
| Extent of disease |
| Locoregional recurrence alone |
17 (54.8%) |
| Metastatic disease alone |
8 (25.8%) |
| Locoregional recurrence plus metastatic disease |
6 (19.4%) |
| Nutritional status |
| Patients at risk of severe weight loss (BMI <20) |
15 (48.4%) |
| Severe weight loss after radiotherapy ( >5% body weight loss in 6 months) |
1 (3.2%) |
| Comorbidities |
16 (51.6%) |
| Myocardial infarction |
2 |
| Peripheral vascular disease |
5 |
| Chronic obstructive pulmonary disease |
6 |
| Diabetes mellitus |
4 |
| Polycystic kidney disease |
1 |
| Chronic kidney disease or |
4 |
| Renal failure during chemoradiation |
|
| Chronic liver disease |
4 |
| Stroke |
1 |
| Perforation of the stomach |
2 |
| Atrial fibrillation |
2 |
| Second malignancy treated with curative intent |
3 |
